CliffBio
small molecule

XARELTO

RIVAROXABAN

Loss of exclusivityAugust 2034latest FDA-listed patent expiry
CompanyJanssen Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameXARELTO
Active ingredientRIVAROXABAN
Strength20MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2011
Marketing statusRX

Listed patents

PatentExpiresType
9539218*PEDAugust 2034—
9539218February 2034use U-3285

More from Janssen Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

XARELTO patent cliff — loss of exclusivity August 2034 | CliffBio